Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Non-Current Assets came in at $10.7 million in Q1 2026, down 81.93% year-on-year from $59.2 million in Q1 2025, and down 7.91% quarter-over-quarter from $11.6 million in Q4 2025.
Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026) Analysis & Trends
Prothena Corp Public's Non-Current Assets history runs 15 years deep, the most recent figure standing at $10.7 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 81.93% year-over-year to $10.7 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 81.93% decrease from a year earlier, with the FY2025 full-year figure at $11.6 million, down 81.18% from the prior year.
- Non-Current Assets retreated to $10.7 million in Q1 2026 per PRTA's latest filing, from $11.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $61.7 million in Q4 2024 and bottomed at $10.7 million in Q1 2026.
- The 5-year median for Non-Current Assets is $41.2 million (2023), against an average of $39.3 million.
- Across the five-year window, Non-Current Assets surged 88.49% in 2023 and plunged 81.93% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $38.9 million in 2022, then jumped by 46.65% to $57.1 million in 2023, then gained by 8.05% to $61.7 million in 2024, then sank by 81.18% to $11.6 million in 2025, then declined by 7.91% to $10.7 million in 2026.
- Per Business Quant, the three latest PRTA Non-Current Assets figures stand at $10.7 million (Q1 2026), $11.6 million (Q4 2025), and $12.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 285.82 Mn |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 10.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.69 Mn |
| Dec 31, 2025 | 11.61 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Jun 30, 2025 | 13.59 Mn |
| Mar 31, 2025 | 59.16 Mn |
| Dec 31, 2024 | 61.70 Mn |
| Sep 30, 2024 | 60.27 Mn |
| Jun 30, 2024 | 59.59 Mn |
| Mar 31, 2024 | 57.33 Mn |
| Dec 31, 2023 | 57.10 Mn |
| Sep 30, 2023 | 56.32 Mn |
| Jun 30, 2023 | 43.55 Mn |
| Mar 31, 2023 | 41.24 Mn |
| Dec 31, 2022 | 38.94 Mn |
| Sep 30, 2022 | 29.88 Mn |
| Jun 30, 2022 | 28.30 Mn |
| Mar 31, 2022 | 25.79 Mn |
| Dec 31, 2021 | 24.56 Mn |
| Sep 30, 2021 | 25.17 Mn |
| Jun 30, 2021 | 26.91 Mn |